A A Hamid1, H-C Huang2, V Wang3, Y-H Chen3, F Feng4, R Den5, G Attard6, E M Van Allen7, P T Tran8, D E Spratt9, R Dittamore2, E Davicioni2, G Liu10, R DiPaola11, M A Carducci8, C J Sweeney12. 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; University of Melbourne, Melbourne, Australia. 2. Decipher Biosciences, San Diego, USA. 3. Department of Data Science, Dana-Farber Cancer Institute, Boston, USA. 4. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA. 5. Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, USA. 6. University College London Cancer Institute, London, UK. 7. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. 8. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, USA. 9. Department of Radiation Oncology, University of Michigan, Ann Arbor, USA. 10. University of Wisconsin Carbone Cancer Center, Madison, USA. 11. University of Kentucky Medical Center, Lexington, USA. 12. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. Electronic address: Christopher_Sweeney@dfci.harvard.edu.
Abstract
BACKGROUND: The phase III CHAARTED trial established upfront androgen-deprivation therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate cancer (mHSPC) based on meaningful improvement in overall survival (OS). Biological prognostic markers of outcomes and predictors of chemotherapy benefit are undefined. PATIENTS AND METHODS: Whole transcriptomic profiling was performed on primary PC tissue obtained from patients enrolled in CHAARTED prior to systemic therapy. We adopted an a priori analytical plan to test defined RNA signatures and their associations with HSPC clinical phenotypes and outcomes. Multivariable analyses (MVAs) were adjusted for age, Eastern Cooperative Oncology Group status, de novo metastasis presentation, volume of disease, and treatment arm. The primary endpoint was OS; the secondary endpoint was time to castration-resistant PC. RESULTS: The analytic cohort of 160 patients demonstrated marked differences in transcriptional profile compared with localized PC, with a predominance of luminal B (50%) and basal (48%) subtypes, lower androgen receptor activity (AR-A), and high Decipher risk disease. Luminal B subtype was associated with poorer prognosis on ADT alone but benefited significantly from ADT + D [OS: hazard ratio (HR) 0.45; P = 0.007], in contrast to basal subtype which showed no OS benefit (HR 0.85; P = 0.58), even in those with high-volume disease. Higher Decipher risk and lower AR-A were significantly associated with poorer OS in MVA. In addition, higher Decipher risk showed greater improvements in OS with ADT + D (HR 0.41; P = 0.015). CONCLUSION: This study demonstrates the utility of transcriptomic subtyping to guide prognostication in mHSPC and potential selection of patients for chemohormonal therapy, and provides proof of concept for the possibility of biomarker-guided selection of established combination therapies in mHSPC.
BACKGROUND: The phase III CHAARTED trial established upfront androgen-deprivation therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate cancer (mHSPC) based on meaningful improvement in overall survival (OS). Biological prognostic markers of outcomes and predictors of chemotherapy benefit are undefined. PATIENTS AND METHODS: Whole transcriptomic profiling was performed on primary PC tissue obtained from patients enrolled in CHAARTED prior to systemic therapy. We adopted an a priori analytical plan to test defined RNA signatures and their associations with HSPC clinical phenotypes and outcomes. Multivariable analyses (MVAs) were adjusted for age, Eastern Cooperative Oncology Group status, de novo metastasis presentation, volume of disease, and treatment arm. The primary endpoint was OS; the secondary endpoint was time to castration-resistant PC. RESULTS: The analytic cohort of 160 patients demonstrated marked differences in transcriptional profile compared with localized PC, with a predominance of luminal B (50%) and basal (48%) subtypes, lower androgen receptor activity (AR-A), and high Decipher risk disease. Luminal B subtype was associated with poorer prognosis on ADT alone but benefited significantly from ADT + D [OS: hazard ratio (HR) 0.45; P = 0.007], in contrast to basal subtype which showed no OS benefit (HR 0.85; P = 0.58), even in those with high-volume disease. Higher Decipher risk and lower AR-A were significantly associated with poorer OS in MVA. In addition, higher Decipher risk showed greater improvements in OS with ADT + D (HR 0.41; P = 0.015). CONCLUSION: This study demonstrates the utility of transcriptomic subtyping to guide prognostication in mHSPC and potential selection of patients for chemohormonal therapy, and provides proof of concept for the possibility of biomarker-guided selection of established combination therapies in mHSPC.
Authors: Kim N Chi; Neeraj Agarwal; Anders Bjartell; Byung Ha Chung; Andrea J Pereira de Santana Gomes; Robert Given; Álvaro Juárez Soto; Axel S Merseburger; Mustafa Özgüroğlu; Hirotsugu Uemura; Dingwei Ye; Kris Deprince; Vahid Naini; Jinhui Li; Shinta Cheng; Margaret K Yu; Ke Zhang; Julie S Larsen; Sharon McCarthy; Simon Chowdhury Journal: N Engl J Med Date: 2019-05-31 Impact factor: 91.245
Authors: Wassim Abida; Joshua Armenia; Anuradha Gopalan; Ryan Brennan; Michael Walsh; David Barron; Daniel Danila; Dana Rathkopf; Michael Morris; Susan Slovin; Brigit McLaughlin; Kristen Curtis; David M Hyman; Jeremy C Durack; Stephen B Solomon; Maria E Arcila; Ahmet Zehir; Aijazuddin Syed; Jianjiong Gao; Debyani Chakravarty; Hebert Alberto Vargas; Mark E Robson; Vijai Joseph; Kenneth Offit; Mark T A Donoghue; Adam A Abeshouse; Ritika Kundra; Zachary J Heins; Alexander V Penson; Christopher Harris; Barry S Taylor; Marc Ladanyi; Diana Mandelker; Liying Zhang; Victor E Reuter; Philip W Kantoff; David B Solit; Michael F Berger; Charles L Sawyers; Nikolaus Schultz; Howard I Scher Journal: JCO Precis Oncol Date: 2017-05-31
Authors: Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Andrea Sboner; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan Journal: Cell Date: 2015-07-16 Impact factor: 41.582
Authors: Barry S Taylor; Nikolaus Schultz; Haley Hieronymus; Anuradha Gopalan; Yonghong Xiao; Brett S Carver; Vivek K Arora; Poorvi Kaushik; Ethan Cerami; Boris Reva; Yevgeniy Antipin; Nicholas Mitsiades; Thomas Landers; Igor Dolgalev; John E Major; Manda Wilson; Nicholas D Socci; Alex E Lash; Adriana Heguy; James A Eastham; Howard I Scher; Victor E Reuter; Peter T Scardino; Chris Sander; Charles L Sawyers; William L Gerald Journal: Cancer Cell Date: 2010-06-24 Impact factor: 31.743
Authors: Anis A Hamid; Kathryn P Gray; Grace Shaw; Laura E MacConaill; Carolyn Evan; Brandon Bernard; Massimo Loda; Niall M Corcoran; Eliezer M Van Allen; Atish D Choudhury; Christopher J Sweeney Journal: Eur Urol Date: 2018-12-12 Impact factor: 20.096
Authors: Daniel E Spratt; Mohammed Alshalalfa; Nick Fishbane; Adam B Weiner; Rohit Mehra; Brandon A Mahal; Jonathan Lehrer; Yang Liu; Shuang G Zhao; Corey Speers; Todd M Morgan; Adam P Dicker; Stephen J Freedland; R Jeffery Karnes; Sheila Weinmann; Elai Davicioni; Ashley E Ross; Robert B Den; Paul L Nguyen; Felix Y Feng; Tamara L Lotan; Arul M Chinnaiyan; Edward M Schaeffer Journal: Clin Cancer Res Date: 2019-09-12 Impact factor: 12.531
Authors: Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Peter De Porre; Thian Kheoh; Youn C Park; Mary B Todd; Kim N Chi Journal: N Engl J Med Date: 2017-06-04 Impact factor: 91.245
Authors: Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar Journal: Lancet Date: 2015-12-21 Impact factor: 79.321
Authors: Joshi J Alumkal; Duanchen Sun; Eric Lu; Tomasz M Beer; George V Thomas; Emile Latour; Rahul Aggarwal; Jeremy Cetnar; Charles J Ryan; Shaadi Tabatabaei; Shawna Bailey; Claire B Turina; David A Quigley; Xiangnan Guan; Adam Foye; Jack F Youngren; Joshua Urrutia; Jiaoti Huang; Alana S Weinstein; Verena Friedl; Matthew Rettig; Robert E Reiter; Daniel E Spratt; Martin Gleave; Christopher P Evans; Joshua M Stuart; Yiyi Chen; Felix Y Feng; Eric J Small; Owen N Witte; Zheng Xia Journal: Proc Natl Acad Sci U S A Date: 2020-05-18 Impact factor: 11.205
Authors: Philip Sutera; Matthew P Deek; Kim Van der Eecken; Alexander W Wyatt; Amar U Kishan; Jason K Molitoris; Matthew J Ferris; M Minhaj Siddiqui; Zaker Rana; Mark V Mishra; Young Kwok; Elai Davicioni; Daniel E Spratt; Piet Ost; Felix Y Feng; Phuoc T Tran Journal: Prostate Date: 2022-08 Impact factor: 4.012
Authors: Adam B Weiner; Christina Y Yu; Mitali Kini; Yang Liu; Elai Davicioni; Antonina Mitrofanova; Tamara L Lotan; Edward M Schaeffer Journal: Prostate Cancer Prostatic Dis Date: 2022-05-14 Impact factor: 5.455
Authors: Ilsa M Coleman; Navonil DeSarkar; Colm Morrissey; Li Xin; Martine P Roudier; Erolcan Sayar; Dapei Li; Eva Corey; Michael C Haffner; Peter S Nelson Journal: Clin Cancer Res Date: 2022-07-15 Impact factor: 13.801
Authors: Elin Thysell; Linda Köhn; Julius Semenas; Helena Järemo; Eva Freyhult; Marie Lundholm; Camilla Thellenberg Karlsson; Jan-Erik Damber; Anders Widmark; Sead Crnalic; Andreas Josefsson; Karin Welén; Rolf J A Nilsson; Anders Bergh; Pernilla Wikström Journal: Mol Oncol Date: 2021-12-27 Impact factor: 6.603